Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) traded up 5.7% during mid-day trading on Thursday . The company traded as high as $6.99 and last traded at $6.66, with a volume of 651,265 shares trading hands. The stock had previously closed at $6.30.

A number of analysts recently issued reports on the company. Zacks Investment Research upgraded Anavex Life Sciences Corp. from a “hold” rating to a “buy” rating and set a $5.00 price objective on the stock in a research note on Tuesday, May 31st. Maxim Group reiterated a “buy” rating and set a $15.00 price objective on shares of Anavex Life Sciences Corp. in a research note on Wednesday, May 11th. Finally, FBR & Co reiterated a “buy” rating on shares of Anavex Life Sciences Corp. in a research note on Wednesday, June 22nd.

The firm’s market capitalization is $246.40 million. The company has a 50-day moving average of $4.60 and a 200-day moving average of $4.78.

Anavex Life Sciences Corp. (NASDAQ:AVXL) last issued its earnings results on Wednesday, May 11th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.10. On average, equities analysts predict that Anavex Life Sciences Corp. will post ($0.34) EPS for the current year.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.